Literature DB >> 7848576

Oncogenic osteomalacia: a clinicopathologic study of 17 bone lesions.

Y K Park1, K K Unni, J W Beabout, S F Hodgson.   

Abstract

Oncogenic osteomalacia is an unusual and rare clinicopathologic syndrome characterized by mesenchymal tumors that apparently produce osteomalacia and biochemical abnormalities consisting of hypophosphatemia, normocalcemia, and increased levels of alkaline phosphatase. We collected from the Mayo Clinic files and from our consultation files the records for 17 cases of osteomalacia associated with bone lesions. There were five cases of fibrous dysplasia, three of hemangiopericytoma, and two of phosphaturic mesenchymal tumor. There was one case each of osteosarcoma, chondroblastoma, chondromyxoid fibroma, malignant fibrous histiocytoma, giant cell tumor, metaphyseal fibrous defect, and hemangioma. In this study we can figure out that the most common characteristic histologic features of our cases were hemangiopericytomatous vascular proliferation, fine lace-like stromal calcification, and stromal giant cells. In most of the cases, the clinical and biochemical symptoms and signs resolved soon after complete resection of the lesion. When the lesion recurred or metastasized, the symptoms and signs also recurred.

Entities:  

Mesh:

Year:  1994        PMID: 7848576      PMCID: PMC3054097          DOI: 10.3346/jkms.1994.9.4.289

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  11 in total

1.  Tumor-Induced Osteomalacia.

Authors:  Rajiv Kumar; Andrew L Folpe; Brian P Mullan
Journal:  Transl Endocrinol Metab       Date:  2015

2.  Phosphaturic mesenchymal tumor with chondromyxoid fibroma-like feature: an unusual morphological appearance.

Authors:  Pallavi Suryawanshi; Manish Agarwal; Rahul Dhake; Saral Desai; Bharat Rekhi; Kishor B Reddy; Nirmala Ajit Jambhekar
Journal:  Skeletal Radiol       Date:  2011-05-01       Impact factor: 2.199

3.  Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia.

Authors:  Yasuo Imanishi; Jun Hashimoto; Wataru Ando; Keisuke Kobayashi; Takafumi Ueda; Yuki Nagata; Akimitsu Miyauchi; Hajime M Koyano; Hiroshi Kaji; Takatoshi Saito; Koichi Oba; Yasato Komatsu; Tomoaki Morioka; Katsuhito Mori; Takami Miki; Masaaki Inaba
Journal:  J Bone Miner Metab       Date:  2011-07-08       Impact factor: 2.626

4.  Phosphaturic mesenchymal tumor: two contrasting cases.

Authors:  Monica C Koplas; Brian P Rubin; Murali Sundaram
Journal:  Skeletal Radiol       Date:  2014-01-09       Impact factor: 2.199

Review 5.  McCune Albright syndrome and hypophosphatemic rickets.

Authors:  S Dutta; A Bagga
Journal:  Indian J Pediatr       Date:  1999 Jul-Aug       Impact factor: 1.967

6.  Persistent phosphaturic mesenchymal tumor causing tumor-induced osteomalacia treated with image-guided ablation.

Authors:  J C Horng; E Van Eperen; S Tutton; R Singh; J L Shaker; A N Wooldridge
Journal:  Osteoporos Int       Date:  2021-03-02       Impact factor: 4.507

7.  Phosphaturic mesenchymal tumour mixed connective tissue variant: report of three cases with unusual histological findings.

Authors:  David A Shustik; David Ce Ng; Kesavan Sittampalam
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

8.  Locally aggressive and multifocal phosphaturic mesenchymal tumors: two unusual cases of tumor-induced osteomalacia.

Authors:  Meghan Higley; Brooke Beckett; Sandra Schmahmann; Elizabeth Dacey; Erik Foss
Journal:  Skeletal Radiol       Date:  2015-09-04       Impact factor: 2.199

9.  Oncogenic osteomalacia: Problems in diagnosis and long-term management.

Authors:  Ish K Dhammi; Anil K Jain; Ajay Pal Singh; Puneet Mishra; Saurabh Jain
Journal:  Indian J Orthop       Date:  2010-10       Impact factor: 1.251

10.  Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis: Case report and literature review.

Authors:  Aman Gupta; Abhishek Dwivedi; Priyanka Patel; Somya Gupta
Journal:  Indian J Radiol Imaging       Date:  2015 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.